HCV NS5B RNA-dependent RNA polymerase and HCV NS5A protein — Drug Target

All drugs that target HCV NS5B RNA-dependent RNA polymerase and HCV NS5A protein — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

NS5B RNA-dependent RNA polymerase inhibitor and NS5A inhibitor

Phase 3 pipeline (1)

• Sofosbuvir and Daklatasuvir · Sherief Abd-Elsalam · NS5B RNA-dependent RNA polymerase inhibitor and NS5A inhibitor · Infectious Disease
  Sofosbuvir and Daklatasuvir work together to inhibit the HCV NS5B RNA-dependent RNA polymerase and NS5A protein, respectively, to treat hepatitis C virus infection.